 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || Tyvyt (sintilimab) / Eli Lilly, IBI360 / Innovent Biologics
Trial completion, Phase classification, Enrollment change, Combination therapy, Monotherapy, Metastases: A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Oct 17, 2024
P1, N=12, Completed, Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Recruiting --> Completed | Phase classification: P1a/1b --> P1 | N=48 --> 12
- || Tyvyt (sintilimab) / Eli Lilly, IBI360 / Innovent Biologics
Enrollment open, Combination therapy, Monotherapy, Metastases: A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Dec 17, 2021
P1a/1b, N=48, Recruiting, Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Recruiting --> Completed | Phase classification: P1a/1b --> P1 | N=48 --> 12 Not yet recruiting --> Recruiting
- || Tyvyt (sintilimab) / Eli Lilly, IBI360 / Innovent Biologics
New P1 trial, Combination therapy, Monotherapy, Metastases: A Phase Ia/Ib Clinical Trial of IBI360 Monotherapy or in Combination With Sintilimab and (or) Chemotherapy in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Sep 14, 2021
P1a/1b, N=48, Not yet recruiting, Sponsor: Innovent Biologics (Suzhou) Co. Ltd.